Handbook of experimental pharmacology最新文献_第2页

Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis. 生物活性黄酮类化合物在防止内皮功能障碍和动脉粥样硬化方面的作用

Handbook of experimental pharmacology Pub Date : 2025-01-01 DOI: 10.1007/164_2024_715

Yanjun Yin, Jingjing Xu, Iqra Ilyas, Suowen Xu

{"title":"Bioactive Flavonoids in Protecting Against Endothelial Dysfunction and Atherosclerosis.","authors":"Yanjun Yin, Jingjing Xu, Iqra Ilyas, Suowen Xu","doi":"10.1007/164_2024_715","DOIUrl":"10.1007/164_2024_715","url":null,"abstract":"Atherosclerosis is a common cardiovascular disease closely associated with factors such as hyperlipidaemia and chronic inflammation. Among them, endothelial dysfunction serves as a major predisposing factor. Vascular endothelial dysfunction is manifested by impaired endothelium-dependent vasodilation, enhanced oxidative stress, chronic inflammation, leukocyte adhesion and hyperpermeability, endothelial senescence, and endothelial-mesenchymal transition (EndoMT). Flavonoids are known for their antioxidant activity, eliminating oxidative stress induced by reactive oxygen species (ROS), thereby preventing the oxidation of low-density lipoprotein (LDL) cholesterol, reducing platelet aggregation, alleviating ischemic damage, and improving vascular function. Flavonoids have also been shown to possess anti-inflammatory activity and to protect the cardiovascular system. This review focuses on the protective effects of these naturally-occuring bioactive flavonoids against the initiation and progression of atherosclerosis through their effects on endothelial cells including, but not limited to, their antioxidant, anti-inflammatory, anti-thrombotic, and lipid-lowering properties. However, more clinical evidences are still needed to determine the exact role and optimal dosage of these compounds in the treatment of atherosclerosis.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"1-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Products Derived from Cannabis sativa for Pain Management. 从大麻中提取的用于止痛的天然产品。

Handbook of experimental pharmacology Pub Date : 2025-01-01 DOI: 10.1007/164_2024_710

Erika Liktor-Busa, Tally M Largent-Milnes

{"title":"Natural Products Derived from Cannabis sativa for Pain Management.","authors":"Erika Liktor-Busa, Tally M Largent-Milnes","doi":"10.1007/164_2024_710","DOIUrl":"10.1007/164_2024_710","url":null,"abstract":"Cannabis sativa is one of the oldest medicinal plants in human history. Even ancient physicians from hundreds of years ago used Cannabis sativa to treat several conditions like pain. In the modern era, the research community, including health-care providers, have witnessed wide-scale changes in cannabis policy, legislation, and marketing, with a parallel increase in patient interest. A simple search in PubMed using \"cannabis and pain\" as keywords provides more than 2,400 articles, about 80% of which were published in the last 8-10 years. Several advancements have been achieved in understanding the complex chemistry of cannabis along with its multiple pharmacological activities. Preclinical data have demonstrated evidence for the promising potential of cannabis for pain management, and the continuous rise in the prevalence of pain increases the urgency to translate this into clinical practice. Despite the large body of cannabis literature, researchers still need to find rigorous answers for the questions about the efficacy and safety of cannabis in treatment of certain disorders such as pain. In the current chapter, we seek to present a critical overview about the current knowledge on cannabis with special emphasis on pain-related disorders.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"239-263"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Products in the Clinical Management of Metabolic Syndrome. 代谢综合征临床治疗中的天然产品。

Handbook of experimental pharmacology Pub Date : 2025-01-01 DOI: 10.1007/164_2024_711

Ozra Tabatabaei-Malazy, Narges Lavari, Mohammad Abdollahi

{"title":"Natural Products in the Clinical Management of Metabolic Syndrome.","authors":"Ozra Tabatabaei-Malazy, Narges Lavari, Mohammad Abdollahi","doi":"10.1007/164_2024_711","DOIUrl":"10.1007/164_2024_711","url":null,"abstract":"Metabolic syndrome (MetS) is a prevalent health condition that requires significant attention and intervention due to its multifaceted nature. It encompasses a variety of ailments such as diabetes mellitus, hypertension, obesity, and dyslipidemia. Despite extensive research, the underlying pathophysiology of MetS is not entirely understood, and current synthetic drugs used to treat it have adverse effects and can be expensive. Therefore, natural products are being investigated as a potential alternative treatment for MetS. This chapter provides an overview of studies on natural products as a treatment for MetS. The available evidence suggests that bioactive phytochemicals and herbal medicines, such as curcumin, resveratrol, Nigella sativa, Hibiscus sabdariffa, and Theobroma cacao, have the potential to treat MetS effectively. Furthermore, natural products can be explored as a novel drug discovery approach for MetS. However, it is imperative to conduct well-designed randomized controlled trials with large sample sizes to confirm these findings. Based on our review, we conclude that natural products could be a promising alternative for treating MetS. Further research is warranted to explore this potential fully. The use of natural products for MetS treatment could reduce the reliance on synthetic drugs, many of which have harmful side effects and are costly. The development of natural products as a treatment for MetS could have significant implications for public health, and we encourage further research in this area.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"123-157"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Products to Promote Vascular Health. 促进血管健康的天然产品。

Handbook of experimental pharmacology Pub Date : 2025-01-01 DOI: 10.1007/164_2024_721

Valérie B Schini-Kerth, Ibrahima Diouf, Hira Muzammel, Amissi Said, Cyril Auger

{"title":"Natural Products to Promote Vascular Health.","authors":"Valérie B Schini-Kerth, Ibrahima Diouf, Hira Muzammel, Amissi Said, Cyril Auger","doi":"10.1007/164_2024_721","DOIUrl":"10.1007/164_2024_721","url":null,"abstract":"Maintaining good vascular health is a major component in healthy ageing as it reduces the risk of cardiovascular diseases. Endothelial dysfunction, in particular, is a key mechanism in the development of major cardiovascular diseases including hypertension, atherosclerosis and diabetes. Recently, endothelial senescence has emerged as a pivotal early event in age-related endothelial dysfunction. Endothelial function is characterized by an imbalance between the endothelial formation of vasoprotective mechanisms, including the formation of nitric oxide (NO) and endothelium-dependent hyperpolarization responses, and an increased level of oxidative stress involving several pro-oxidant enzymes such as NADPH oxidases and, often also, the appearance of cyclooxygenase-derived vasoconstrictors. Pre-clinical studies have indicated that natural products, in particular several polyphenol-rich foods, can trigger activating pathways in endothelial cells promoting an increased formation of NO and endothelium-dependent hyperpolarization. In addition, some can even exert beneficial effects on endothelial senescence. Moreover, some of these products have been associated with the prevention and/or improvement of established endothelial dysfunction in several experimental models of cardiovascular diseases and in humans with cardiovascular diseases. Therefore, intake of certain natural products, such as dietary and plant-derived polyphenol-rich products, appears to be an attractive approach for a healthy vascular system in ageing.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"33-60"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Is QSP and Why Does It Exist?: A Brief History. 什么是QSP，它为什么存在？：简史。

Handbook of experimental pharmacology Pub Date : 2024-12-31 DOI: 10.1007/164_2024_733

Christina Friedrich

引用次数: 0

Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction. 免疫肿瘤学中的定量系统药理学模型：假设检验、剂量优化和疗效预测。

Handbook of experimental pharmacology Pub Date : 2024-12-21 DOI: 10.1007/164_2024_735

Hanwen Wang, Theinmozhi Arulraj, Alberto Ippolito, Aleksander S Popel

{"title":"Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction.","authors":"Hanwen Wang, Theinmozhi Arulraj, Alberto Ippolito, Aleksander S Popel","doi":"10.1007/164_2024_735","DOIUrl":"https://doi.org/10.1007/164_2024_735","url":null,"abstract":"Despite an increasing number of clinical trials, cancer is one of the leading causes of death worldwide in the past decade. Among all complex diseases, clinical trials in oncology have among the lowest success rates, in part due to the high intra- and inter-tumoral heterogeneity. There are more than a thousand cancer drugs and treatment combinations being investigated in ongoing clinical trials for various cancer subtypes, germline mutations, metastasis, etc. Particularly, treatments relying on the (re)activation of the immune system have become increasingly present in the clinical trial pipeline. However, the complexities of the immune response and cancer-immune interactions pose a challenge to the development of these therapies. Quantitative systems pharmacology (QSP), as a computational approach to predict tumor response to treatments of interest, can be used to conduct in silico clinical trials with virtual patients (and emergent use of digital twins) in place of real patients, thus lowering the time and cost of clinical trials. In line with improved mechanistic understanding of the human immune system and promising results from recent cancer immunotherapy, QSP models can play critical roles in model-informed drug development in immuno-oncology. In this chapter, we discuss how QSP models were designed to serve different study objectives, including hypothesis testing, dose optimization, and efficacy prediction, via case studies in immuno-oncology.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of Quantitative Systems Pharmacology Approaches to Support Pediatric Labeling in Rare Diseases. 应用定量系统药理学方法支持罕见疾病的儿科标签。

Handbook of experimental pharmacology Pub Date : 2024-12-14 DOI: 10.1007/164_2024_734

Susana Zaph, Randolph J Leiser, Mengdi Tao, Chanchala Kaddi, Christine Xu

引用次数: 0

Advanced Formulation Approaches for Proteins. 蛋白质的高级配方方法。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_647

Corinna S Schlosser, Gareth R Williams, Karolina Dziemidowicz

引用次数: 0

Adrenal Anion Channels: New Roles in Zona Glomerulosa Physiology and in the Pathophysiology of Primary Aldosteronism. 肾上腺阴离子通道：肾小球生理学和原发性醛固酮增多症病理生理学中的新角色。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_680

Gabriel Stölting, Ute I Scholl

引用次数: 0

β-Adrenoceptors in Cancer: Old Players and New Perspectives. 癌症中的β-肾上腺素受体:老玩家和新视角。

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI: 10.1007/164_2023_701

Rosario Amato, Martina Lucchesi, Silvia Marracci, Luca Filippi, Massimo Dal Monte

{"title":"β-Adrenoceptors in Cancer: Old Players and New Perspectives.","authors":"Rosario Amato, Martina Lucchesi, Silvia Marracci, Luca Filippi, Massimo Dal Monte","doi":"10.1007/164_2023_701","DOIUrl":"10.1007/164_2023_701","url":null,"abstract":"Distress, or negative stress, is known to considerably increase the incidence of several diseases, including cancer. There is indeed evidence from pre-clinical models that distress causes a catecholaminergic overdrive that, mainly through the activation of β-adrenoceptors (β-ARs), results in cancer cell growth and cancer progression. In addition, clinical studies have evidenced a role of negative stress in cancer progression. Moreover, plenty of data demonstrates that β-blockers have positive effects in reducing the pro-tumorigenic activity of catecholamines, correlating with better outcomes in some type of cancers as evidenced by several clinical trials. Among β-ARs, β2-AR seems to be the main β-AR subtype involved in tumor development and progression. However, there are data indicating that also β1-AR and β3-AR may be involved in certain tumors. In this chapter, we will review current knowledge on the role of the three β-AR isoforms in carcinogenesis as well as in cancer growth and progression, with particular emphasis on recent studies that are opening new avenues in the use of β-ARs as therapeutic targets in treating tumors.","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"665-688"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0